A new contender just rattled the obesity drug market

fastcompany.com/91405981/a-new-contender-just-rattled-the-obesity-drug-market

An experimental GLP-1 pill from Eli Lilly just outperformed Novo Nordisk’s oral semaglutide. In a new study, Eli Lilly’s oral pill, orforglipron, helped lower diabetes patients blood sugar more and weight better than Novo Nordisk’s (sold under brand names Ozempic, Rybelsus, and Wegovy).…

This story appeared on fastcompany.com, 2025-09-17 18:40:00.
The Entire Business World on a Single Page. Free to Use →